Mesoblast Ltd (MESO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
|2007||Independent Non-Executive Chairman of the Board|
|2014||Chief Executive Officer, Executive Director|
|2016||Vice Chairman of the Board|
|2014||Group Chief Financial Officer|
|2011||General Counsel, Corporate Executive|
- FDA to fast track Mesoblast's cell therapy for heart failure
- BRIEF-Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA
- BRIEF-Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment
- Tiny stem cell companies close in on major heart disease goals
- RPT-Tiny stem cell companies close in on major heart disease goals